The U.S. has announced the first-ever list of 10 prescription drugs that will be subject to price negotiation by Medicare.

The United States government has named ten drugs that will be subject to the first-ever price negotiations by Medicare. This move is a strong effort by the government to tackle the issue of high drug costs. 

The drugs that will be subject to negotiation include treatments for cancer, diabetes, and heart disease, which can be quite expensive. However, the reduction in prices may not have a direct impact on the prices that patients pay at the pharmacy counter. 

The savings from these negotiations will be used by Medicare to put a cap of $2,000 annually on how much members have to pay out of pocket for drugs starting in 2025. The lower prices will take effect in 2026 and are expected to save Medicare around $25 billion per year by 2031.

By  Anita Johnson-Brown

More News from Los Angeles

• News Mix Top News
• Anita Brown's commentary Opinions matter